Alzheimer’s drug reduces plaques, slows disease progression: full results
The amyloid-busting donanemab slowed clinical progression by 22-35% in early stages of condition, researchers say.
The monoclonal antibody donanemab slows clinical progression among patients with early symptomatic Alzheimer’s disease by up to a third compared to placebo, according to a study in JAMA.
Although the headline results were announced via a media statement in May, the full results of the TRAILBLAZER-ALZ 2 trial were published this week to coincide with the 2023 Alzheimer’s Association International Conference, held in Amsterdam, Netherlands.
The Eli Lilly-funded phase III trial examined the efficacy and safety of donanemab in 1736 adults (mean age 73) with early symptomatic Alzheimer’s disease with amyloid and tau pathology.
Participants were randomly assigned to receive IV donanemab or placebo every four weeks for 18 months.
